Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

BACKGROUND: Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker recommended in clinical guidelines as a first-line treatment for NSCLC which harbours an epidermal growth factor receptor (EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Ping-Tee, Aziz, Mohamed Ismail Abdul, Pearce, Fiona, Lim, Wan-Teck, Wu, David Bin-Chia, Ng, Kwong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872570/
https://www.ncbi.nlm.nih.gov/pubmed/29587666
http://dx.doi.org/10.1186/s12885-018-4223-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872570/
https://www.ncbi.nlm.nih.gov/pubmed/29587666
http://dx.doi.org/10.1186/s12885-018-4223-y

Ejemplares similares